Identifying Genetic Factors Influencing the Development of Anti-Drug Antibodies in Inflammatory Bowel Disease: A Scoping Review.

40 Two studies in pediatric IBD populations reported that carriers of HLA-DQA1*05 had an increased risk of ADA formation, with a strong predictive value for LOR and treatment discontinuation with IFX; however, the association did not reach statistical significance. 32 , 39 Another study investigating a pediatric cohort found that carriage of HLA-DQA1*05 was common (58%), but not significantly associated with ADA formation against IFX or ADL. 44 No association with ADA formation was observed in ADL-treated pediatric patients (p = 0.64), 32 suggesting that genetic influence may differ between drugs. 32 , 39 One study reported that HLA-DQA1*05 predicted immunogenicity (OR 6.63, 95% CI 1.53–37.35) and increased risk of LOR (HR 1.80, 95% CI 1.21–2.67), particularly in IFX-treated patients.

also in 111,027 other papers